PHIL Partners with Harrow to Power HarrowRx, One Prescribing Destination for Harrow’s Eye Care Portfolio
Harrow (HROW) and PHIL have launched HarrowRx, a prescribing and patient-access platform for Harrow’s branded eye care portfolio.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
PHIL Inc., the technology-powered patient access platform, today announced its partnership with Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in
One Prescribing Destination for Harrow’s Growing Eye Care Portfolio
HarrowRx builds on the companies’ established partnership to improve patient access and affordability. Supporting products across Harrow’s entire eye care portfolio, including VEVYE®, HarrowRx is designed to simplify the steps that follow a treatment decision, giving eye care professionals and their staff fewer specialty pharmacies, fulfillment channels, and patient savings programs to navigate, and giving patients a clearer path to access, afford, and receive their prescribed treatment through a digitally-supported access journey.
HarrowRx is designed to scale this standard of patient-first care. Healthcare providers can e-prescribe to HarrowRx, which routes the prescription to a modern access infrastructure that guides patients through the access experience with built-in support and affordability options available for eligible patients. PHIL supports pharmacy operations and patient-access services for applicable prescription-benefit medicines.
The companies’ existing direct-to-patient program has already demonstrated positive impacts for patients. As one patient described: “I have been getting my prescription for Vevye filled for quite a while with PhilRx. [The experience is] great. I get a reminder when it's time to refill, when it's shipped and when it should be there. Wonderful service!”
“We created HarrowRx to simplify the path from prescription to treatment for patients and build upon the trust providers and patients have in the Harrow brand,” said Mark L. Baum, Chief Executive Officer of Harrow. “With our entire branded portfolio in one place within the EMR, we believe HarrowRx will enhance efficiency for prescribers. PHIL has been a valued partner in supporting pharmacy services and helping patients access their Harrow medicines.”
“Our partnership with Harrow has meaningfully improved eye care access, and HarrowRx takes this strong foundation to the next level. By introducing an integrated pathway for e-prescribing and support throughout the access journey, we are helping ensure the millions of Americans living with chronic eye conditions have a clear, affordable path to treatment,” commented Sahil Naik, Chief Growth Officer, PHIL Inc.
The partnership deepens PHIL’s extensive footprint in ophthalmology alongside its widespread and growing presence in dermatology, women’s health, neurology, and cardiology, all supported by the company’s #1-rated
HarrowRx is now available to eye care providers. To get started, prescribers can search for "HarrowRx" (or its NCPDP ID 3694886 or NPI 1578473732) in the pharmacy finder of a connected EMR, select it, and send the prescription as usual. Fulfillment options and patient-support programs vary by product and eligibility.
About PHIL Inc.
PHIL is a healthcare technology platform that partners with pharmaceutical manufacturers to empower patients with more convenient and affordable access to their prescribed medications. Through PHIL’s digital hub and direct-to-patient platform, PHIL supports access, affordability, and adherence at scale. For more information about PHIL, visit phil.us.
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and diseases of the retina. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261102003021/en/
PHIL Media Contact: Mirah Gocher, Marketing Director, mirah.gocher@phil.us, PHIL Inc
Harrow Investor & Media Contact: Mike Biega, Vice President of Investor Relations and Communications, mbiega@harrowinc.com, 617-913-8890
Source: PHIL Inc.